Diffusion Pharmaceuticals Inc. - FORM 10-K - EX-32.1 - EXHIBIT 32.1 - March 25, 2016

Attached files

file filename
10-K - FORM 10-K - Diffusion Pharmaceuticals Inc.dffn20151231_10k.htm
EX-3.3 - EXHIBIT 3.3 - Diffusion Pharmaceuticals Inc.ex3-3.htm
EX-4.7 - EXHIBIT 4.7 - Diffusion Pharmaceuticals Inc.ex4-7.htm
EX-3.4 - EXHIBIT 3.4 - Diffusion Pharmaceuticals Inc.ex3-4.htm
EX-21.1 - EXHIBIT 21.1 - Diffusion Pharmaceuticals Inc.ex21-1.htm
EX-23.1 - EXHIBIT 23.1 - Diffusion Pharmaceuticals Inc.ex23-1.htm
EX-31.2 - EXHIBIT 31.2 - Diffusion Pharmaceuticals Inc.ex31-2.htm
EX-10.3 - EXHIBIT 10.3 - Diffusion Pharmaceuticals Inc.ex10-3.htm
EX-31.1 - EXHIBIT 31.1 - Diffusion Pharmaceuticals Inc.ex31-1.htm
EX-10.24 - EXHIBIT 10.24 - Diffusion Pharmaceuticals Inc.ex10-24.htm
EX-32.2 - EXHIBIT 32.2 - Diffusion Pharmaceuticals Inc.ex32-2.htm

Exhibit 32.1

 

CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Diffusion Pharmaceuticals Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David G. Kalergis, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

  

/s/ David G. Kalergis

 

 

 

David G. Kalergis

 

   

Chairman and Chief Executive Officer

  

 

 

March 25, 2016

 

Diffusion Pharmaceuticals Inc. Reports